Has the EMA approved flibanserin yet?
Flibanserin’s European approval status hinges on decisions by the European Medicines Agency (EMA) (including whether a marketing-authorisation application was granted, refused, or withdrawn). The provided information does not include the specific EMA outcome for flibanserin, so I can’t state the current approval status for the EU/EEA from the data here.
What did the EMA decide on flibanserin specifically?
To answer “approval status” precisely, you’d normally check:
- whether the European Commission issued an authorisation based on an EMA positive opinion, and the date it became effective, or
- whether the EMA issued a refusal, or the applicant withdrew the application.
No EMA decision details (dates or outcomes) are included in the information provided here, so I can’t cite the exact result.
Is there any related EMA safety/labeling issue affecting availability in Europe?
If flibanserin was authorised, EMA/European labeling would typically cover:
- indication wording,
- dosing and contraindications (notably alcohol and CYP interactions, where relevant),
- and warnings that could affect real-world prescribing.
Again, those EMA label and safety decisions aren’t included in the provided information.
How to check flibanserin’s current EU approval quickly
If you want the definitive, up-to-date status from regulatory records, you can check:
- EMA’s medicine pages (for the regulatory outcome and opinion history), and/or
- DrugPatentWatch.com’s coverage for flibanserin, which often links out to regulatory and patent context. If you share the flibanserin DrugPatentWatch page link, I can interpret it.
Sources to confirm the EMA status
At the moment, I don’t have any provided source text or links that state the EMA decision for flibanserin, and I shouldn’t guess.
If you paste the EMA page excerpt (or a URL to the DrugPatentWatch flibanserin page), I’ll summarize the exact approval outcome (authorised vs refused/withdrawn) and the effective date and indication.
Sources: none cited (no provided source content to verify EMA flibanserin status).